No Data
No Data
Zhejiang Anglikang Pharmaceutical (002940.SZ) plans to distribute CNY 2.1 per 10 shares in 2023, with ex-rights and ex-dividends on June 17.
Zhejiang Anglikang Pharmaceutical (002940.SZ) released an announcement that the company's annual equity distribution plan for 2023 is to distribute 0.8 yuan (taxes included) per share to all shareholders...
Zhejiang Anglikang Pharmaceutical (002940.SZ): Cumulative expenditure of 34.0915 million yuan repurchased 2.02 million shares.
Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that as of May 31, 2024, the company has repurchased a total of 2,020,000 shares through a share buyback dedicated securities account using centralized bidding trading method, accounting for 1.00% of the company's total share capital, with a maximum fill price of 22.35 yuan/share and a minimum fill price of 12.55 yuan/share, for a total trade amount of 34,091,530.04 yuan (excluding transaction fees).
Onlikon (002940.SZ): Haixi Pharmaceutical passed the high-tech enterprise certification
Gelonghui, May 6, 丨 Anglikang (002940.SZ) announced that recently, Fujian Haixi United Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”), a subsidiary of Zhejiang Anglikang Pharmaceutical Co., Ltd., received the “High-tech Enterprise Certificate” approved and issued by the Fujian Provincial Department of Science and Technology, the Fujian Provincial Department of Finance, and the Fujian Provincial Taxation Bureau of the State Administration of Taxation.
Onlikon (002940.SZ): Net profit of 28.218,700 yuan in the first quarter decreased by 40.05% year-on-year
On April 26, Ge Longhui (002940.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 408 million yuan, down 3.89% year on year; net profit attributable to shareholders of listed companies was 28.21887 million yuan, down 40.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 21.5887 million yuan, down 32.33% year on year; basic earnings per share were 0.14 yuan.
Onlikon (002940.SZ) announced its 2023 annual results, with net profit of 138 million yuan, an increase of 8.7% over the previous year
Onlikon (002940.SZ) disclosed its 2023 annual report. The company achieved revenue of 1,626 billion yuan in 2023, an increase of 3.66%; net profit to mother of 138 million yuan, an increase of 8.7%; deducted non-net profit of 107 million yuan, a year-on-year decrease of 11.19%; and basic earnings per share of 0.69 yuan. The company plans to distribute a cash dividend of 2.1 yuan (tax included) for every 10 shares.
Onlikon (002940.SZ): A total of 2.02 million shares have been repurchased as of February 29
Gelonghui (002940.SZ) issued an announcement on March 3, 2024. As of February 29, 2024, the company had repurchased 2.02 million shares through a special stock repurchase securities account, accounting for 1.00% of the company's total share capital. The highest transaction price was 22.35 yuan/share, the minimum transaction price was 12.55 yuan/share, and the total transaction amount was 34,915 million yuan (excluding transaction fees).
No Data